303 related articles for article (PubMed ID: 32083573)
1. Identifying prognostic biomarkers of non-small cell lung cancer by transcriptome analysis.
Xiong Y; Feng Y; Qiao T; Han Y
Cancer Biomark; 2020; 27(2):243-250. PubMed ID: 32083573
[TBL] [Abstract][Full Text] [Related]
2. Bioinformatic analysis revealing mitotic spindle assembly regulated NDC80 and MAD2L1 as prognostic biomarkers in non-small cell lung cancer development.
Wei R; Wang Z; Zhang Y; Wang B; Shen N; E L; Li X; Shang L; Shang Y; Yan W; Zhang X; Ma W; Wang C
BMC Med Genomics; 2020 Aug; 13(1):112. PubMed ID: 32795325
[TBL] [Abstract][Full Text] [Related]
3. Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
Li Y; Sun N; Lu Z; Sun S; Huang J; Chen Z; He J
Cancer Lett; 2017 May; 393():40-51. PubMed ID: 28223168
[TBL] [Abstract][Full Text] [Related]
4. Identification of prognostic biomarkers for major subtypes of non-small-cell lung cancer using genomic and clinical data.
Lathwal A; Kumar R; Arora C; Raghava GPS
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2743-2752. PubMed ID: 32661603
[TBL] [Abstract][Full Text] [Related]
5. The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.
Tian WJ; Liu SS; Li BR
Technol Cancer Res Treat; 2020; 19():1533033820977504. PubMed ID: 33256552
[TBL] [Abstract][Full Text] [Related]
6. System analysis of
Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
[TBL] [Abstract][Full Text] [Related]
7. GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma.
Ning J; Jiang S; Li X; Wang Y; Deng X; Zhang Z; He L; Wang D; Jiang Y
BMC Pulm Med; 2021 Jun; 21(1):199. PubMed ID: 34112123
[TBL] [Abstract][Full Text] [Related]
8. Telomere-associated genes and telomeric lncRNAs are biomarker candidates in lung squamous cell carcinoma (LUSC).
Storti CB; de Oliveira RA; de Carvalho M; Hasimoto EN; Cataneo DC; Cataneo AJM; De Faveri J; Vasconcelos EJR; Dos Reis PP; Cano MIN
Exp Mol Pathol; 2020 Feb; 112():104354. PubMed ID: 31837325
[TBL] [Abstract][Full Text] [Related]
9. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
Yang Y; Wang M; Liu B
J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
[TBL] [Abstract][Full Text] [Related]
10. Expression, Prognosis and Gene Regulation Network of NFAT Transcription Factors in Non-Small Cell Lung Cancer.
Ma J; Du R; Huang Y; Zhong W; Gui H; Mao C; Song X; Lu J
Pathol Oncol Res; 2021; 27():529240. PubMed ID: 34257525
[TBL] [Abstract][Full Text] [Related]
11. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
Xu XL; Gong Y; Zhao DP
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
[TBL] [Abstract][Full Text] [Related]
12. Survival-associated alternative splicing signatures in non-small cell lung cancer.
Zhao D; Zhang C; Jiang M; Wang Y; Liang Y; Wang L; Qin K; Rehman FU; Zhang X
Aging (Albany NY); 2020 Apr; 12(7):5878-5893. PubMed ID: 32282333
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of miR-198-5p in lung squamous cell carcinoma assessed using microarray and RT-qPCR.
Liang YY; Huang JC; Tang RX; Chen WJ; Chen P; Cen WL; Shi K; Gao L; Gao X; Liu AG; Peng XT; Chen G; Huang SN; Fang YY; Gu YY
World J Surg Oncol; 2018 Feb; 16(1):22. PubMed ID: 29394946
[TBL] [Abstract][Full Text] [Related]
14. The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC.
Fu L; Wang H; Wei D; Wang B; Zhang C; Zhu T; Ma Z; Li Z; Wu Y; Yu G
PLoS One; 2020; 15(5):e0233283. PubMed ID: 32437446
[TBL] [Abstract][Full Text] [Related]
15. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
Hou G; Lu Z; Bi Y; Deng J; Yang X
Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321
[TBL] [Abstract][Full Text] [Related]
16. Molecular subtypes based on DNA methylation predict prognosis in lung squamous cell carcinoma.
Li XS; Nie KC; Zheng ZH; Zhou RS; Huang YS; Ye ZJ; He F; Tang Y
BMC Cancer; 2021 Jan; 21(1):96. PubMed ID: 33485313
[TBL] [Abstract][Full Text] [Related]
17. Increased GOLM1 Expression Independently Predicts Unfavorable Overall Survival and Recurrence-Free Survival in Lung Adenocarcinoma.
Liu X; Chen L; Zhang T
Cancer Control; 2018; 25(1):1073274818778001. PubMed ID: 29843532
[TBL] [Abstract][Full Text] [Related]
18. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Li Y; Zheng P; Zhan X
Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
[TBL] [Abstract][Full Text] [Related]
19. Identification and Integrated Analysis of Key Biomarkers for Diagnosis and Prognosis of Non-Small Cell Lung Cancer.
Liu X; Liu X; Li J; Ren F
Med Sci Monit; 2019 Dec; 25():9280-9289. PubMed ID: 31805030
[TBL] [Abstract][Full Text] [Related]
20. [Identification of differentially expressed genes between lung adenocarcinoma and squamous cell carcinoma using transcriber signature analysis].
Peng S; Li X; Liu Q; Zhang Y; Zou L; Gong X; Wang M; Ma X
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jun; 39(6):641-649. PubMed ID: 31270041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
